TY - JOUR AU - Berardi, Rossana PY - 2018 TI - KEYNOTE-024: goodbye to chemotherapy? JF - Journal of Thoracic Disease; Vol 11, Supplement 3 (March 12, 2019): Journal of Thoracic Disease Y2 - 2018 KW - N2 - In the last 2 years the therapeutic landscape of non-small cell lung cancer (NSCLC) has seen a rapid shift with the introduction of immunotherapy into treatment strategy. Studies have demonstrated superior overall survival (OS) for monoclonal antibody therapy, directed against either the PD-1 receptor [nivolumab (1,2) and pembrolizumab (3)] or its ligand [PD-L1, atezolizumab (4,5)], when compared with docetaxel chemotherapy. UR - https://jtd.amegroups.org/article/view/25499